Saldaña-Shumaker Savanah L, Grenning Alexander J, Cunningham Christopher W
Department of Pharmaceutical Sciences, Concordia University Wisconsin, 12800 N. Lake Shore Drive, Mequon, WI 53097, USA.
Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL 32611, USA.
Pharmacol Biochem Behav. 2021 Apr;203:173119. doi: 10.1016/j.pbb.2021.173119. Epub 2021 Jan 26.
The endocannabinoid system, which spans the central and peripheral nervous systems and regulates many biologic processes, is an important target for probe discovery and medications development. Whereas the earliest endocannabinoid receptor probes were derivatives of the non-selective phytocannabinoids isolated from Cannabis species, modern drug discovery techniques have expanded the definitions of what constitutes a CB1R or CB2R cannabinoid receptor ligand. This review highlights recent advances in synthetic cannabinoid receptor chemistry and pharmacology. We provide examples of new CB1R- and CB2R-selective probes, and discuss rational approaches to the design of peripherally-restricted agents. We also describe structural classes of positive- and negative allosteric modulators (PAMs and NAMs) of CB1R and CB2R. Finally, we introduce new opportunities for cannabinoid receptor probe development that have emerged in recent years, including biased agonists that may lead to medications lacking adverse effects.
内源性大麻素系统遍布中枢和外周神经系统,调节多种生物过程,是探针发现和药物开发的重要靶点。尽管最早的内源性大麻素受体探针是从大麻属植物中分离出的非选择性植物大麻素的衍生物,但现代药物发现技术扩展了构成CB1R或CB2R大麻素受体配体的定义。本综述重点介绍了合成大麻素受体化学和药理学的最新进展。我们提供了新的CB1R和CB2R选择性探针的实例,并讨论了设计外周限制剂的合理方法。我们还描述了CB1R和CB2R的正变构调节剂(PAMs)和负变构调节剂(NAMs)的结构类别。最后,我们介绍了近年来出现的大麻素受体探针开发的新机会,包括可能导致无不良反应药物的偏向激动剂。